Apixaban Dosing for Venous Thromboembolism
For acute VTE treatment, start apixaban 10 mg orally twice daily for the first 7 days, then reduce to 5 mg twice daily for continued treatment. 1
Initial Treatment Phase (First 7 Days)
- Dose: 10 mg orally twice daily
- Duration: Exactly 7 days
- No dose adjustment needed for age, weight, or renal function during this acute phase 2, 3, 1
This higher initial dose provides rapid therapeutic anticoagulation without requiring parenteral bridging therapy (unlike dabigatran or edoxaban), which is a key advantage 4.
Maintenance Treatment Phase (After 7 Days)
- Dose: 5 mg orally twice daily
- Duration: Minimum 3 months for provoked VTE; 6 months for unprovoked VTE 2, 3
- No dose reduction criteria exist for VTE treatment based on age, weight, or renal function 5, 6
Critical pitfall: Do NOT apply the atrial fibrillation dose reduction criteria (age ≥80 years, weight ≤60 kg, creatinine ≥1.5 mg/dL) to VTE patients. 5 This is the most common prescribing error with apixaban, leading to inappropriate underdosing in up to 40% of cases. The VTE indication requires full-dose therapy regardless of these factors.
Extended/Secondary Prevention (After ≥6 Months)
After completing at least 6 months of full-dose treatment, reduce to 2.5 mg orally twice daily for extended prophylaxis against recurrent VTE. 2, 7, 1
This reduced dose is appropriate for:
- Patients requiring indefinite anticoagulation
- Those with unprovoked VTE or persistent risk factors
- Cancer-associated VTE after initial treatment phase 8, 9
The 2.5 mg twice daily dose provides effective secondary prevention with significantly lower bleeding rates compared to continuing 5 mg twice daily, particularly in cancer patients (12.1% vs 15.6% clinically relevant bleeding). 8
Renal Function Considerations
Unlike atrial fibrillation, there are NO FDA-approved dose reductions for apixaban in VTE based on renal function alone. 1, 6
- CrCl >30 mL/min: Use standard VTE dosing
- CrCl 15-29 mL/min: Not studied; use with extreme caution or consider alternative (LMWH preferred)
- CrCl <15 mL/min or dialysis: Avoid apixaban 10
Special Populations
Cancer patients: Use the same dosing regimen (10 mg BID × 7 days → 5 mg BID). 3 Apixaban is preferred over LMWH for most cancer-associated VTE, except in patients with gastric or gastroesophageal tumors where bleeding risk is substantially higher with DOACs. 3 In these cases, LMWH remains preferred.
Drug interactions: Reduce dose by 50% when combined P-gp and strong CYP3A4 inhibitors (ketoconazole, ritonavir, itraconazole) are used. 1 If already on 2.5 mg BID, avoid these combinations entirely.
Obesity: No dose adjustment needed regardless of BMI or weight. 11
VTE Prophylaxis Post-Surgery
For orthopedic surgery prophylaxis only:
- Dose: 2.5 mg orally twice daily
- Start: 12-24 hours post-surgery
- Duration: 35 days (hip replacement) or 12 days (knee replacement) 1
Key Clinical Pearls
The AMPLIFY trial 4 demonstrated that this fixed-dose regimen (10 mg BID × 7 days → 5 mg BID) was noninferior to enoxaparin/warfarin for VTE treatment with 69% less major bleeding (0.6% vs 1.8%, P<0.001).
Avoid these common errors:
- Reducing to 2.5 mg BID too early (must complete ≥6 months at 5 mg BID first)
- Applying atrial fibrillation dose reduction criteria to VTE patients
- Dose reducing for "perceived bleeding risk" without meeting specific criteria 5
- Using apixaban in gastric/gastroesophageal cancer without careful consideration 3
Timing of doses: If a dose is missed, take as soon as remembered on the same day, then resume twice-daily schedule. Never double the dose. 1